CN115645376B - Efficient double-layer coated tilmicosin pellets and preparation method thereof - Google Patents
Efficient double-layer coated tilmicosin pellets and preparation method thereof Download PDFInfo
- Publication number
- CN115645376B CN115645376B CN202211320346.0A CN202211320346A CN115645376B CN 115645376 B CN115645376 B CN 115645376B CN 202211320346 A CN202211320346 A CN 202211320346A CN 115645376 B CN115645376 B CN 115645376B
- Authority
- CN
- China
- Prior art keywords
- tilmicosin
- quick
- dissolving
- pill core
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 title claims abstract description 139
- 229960000223 tilmicosin Drugs 0.000 title claims abstract description 137
- 239000008188 pellet Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims description 18
- 239000003814 drug Substances 0.000 claims abstract description 83
- 239000011248 coating agent Substances 0.000 claims abstract description 54
- 238000000576 coating method Methods 0.000 claims abstract description 51
- 229940079593 drug Drugs 0.000 claims abstract description 46
- 239000006187 pill Substances 0.000 claims abstract description 44
- 239000000463 material Substances 0.000 claims abstract description 39
- 238000003756 stirring Methods 0.000 claims abstract description 27
- 239000010410 layer Substances 0.000 claims abstract description 25
- 239000007787 solid Substances 0.000 claims abstract description 15
- 239000011247 coating layer Substances 0.000 claims abstract description 13
- 238000002844 melting Methods 0.000 claims abstract description 9
- 230000008018 melting Effects 0.000 claims abstract description 9
- 239000011162 core material Substances 0.000 claims description 51
- 235000019640 taste Nutrition 0.000 claims description 22
- 230000000873 masking effect Effects 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000004816 latex Substances 0.000 claims description 15
- 229920000126 latex Polymers 0.000 claims description 15
- 229920000858 Cyclodextrin Polymers 0.000 claims description 14
- 239000002270 dispersing agent Substances 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000155 melt Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 11
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 10
- 229920001531 copovidone Polymers 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 238000010288 cold spraying Methods 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 239000004925 Acrylic resin Substances 0.000 claims description 8
- 239000001116 FEMA 4028 Substances 0.000 claims description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
- 229960004853 betadex Drugs 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- -1 fatty acid ester Chemical class 0.000 claims description 6
- 229920001993 poloxamer 188 Polymers 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000004353 Polyethylene glycol 8000 Substances 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 claims description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000007962 solid dispersion Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 235000019658 bitter taste Nutrition 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000002131 composite material Substances 0.000 abstract description 5
- 239000000428 dust Substances 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 239000002245 particle Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
- 241000282887 Suidae Species 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000021095 detection of chemical stimulus involved in sensory perception of bitter taste Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
- Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an efficient double-layer coated pellet of tilmicosin, belonging to the technical field of animal medicines. The pill core is prepared by adopting a solid dispersion melting method, and tilmicosin is uniformly dispersed in the partner-type composite auxiliary materials at a molecular level, so that the bioavailability is higher; the quick-release drug coating layer makes the release speed faster; the taste-masking coating masks the peculiar smell of the medicine and can not refusal to eat. The product has round appearance, good fluidity, no bitter taste or dust, and uniform solid administration and stirring. The pharmacokinetic test comparison proves that the product has the advantages of quick absorption speed, quick response, high blood concentration and good curative effect in vivo after oral administration.
Description
Technical Field
The invention relates to the technical field of animal medicines, in particular to an efficient double-layer coated tilmicosin pellet and a preparation method thereof.
Background
Tilmicosin is a special drug for animals, has inhibiting effect on gram-positive bacteria, certain gram-negative bacteria, mycoplasma, spirochetes and the like, is clinically used for preventing and treating livestock pneumonia (caused by infection of actinobacillus pleuropneumoniae, pasteurella, mycoplasma and the like), poultry mycoplasma disease and mastitis of lactating animals, and has extremely wide application prospect in animal health care. Tilmicosin is indissolvable in water, and liquid preparations such as injection, solution and the like which are clinically related are all required to be added with a large amount of organic solvents as solubilizers and stability, so that the addition of the organic solvents is extremely easy to generate harm such as organism allergy or toxicity, has higher cost and pollutes the environment, and is contrary to the green environmental protection and maintenance concept advocated by the state.
The tilmicosin premix in the current market is two, one is a powder preparation which is directly mixed with auxiliary materials, the bitter taste is high, the bitter taste is diffused in the material mixing process, the powder dust inhaled by the mouth and nose of a feeding person is easy to generate anaphylaxis, the medicine has irritation to the stomach, and the animal does not want to eat; the other is tilmicosin granules, and the problems of uneven stirring, inaccurate dosage, diffuse dust, easy occurrence of adverse reaction by operators and the like are caused by uneven granule sizes. Tilmicosin has poor water solubility, and oral in vivo drug crystals are insoluble and non-dispersible, so that gastrointestinal mucosa is stimulated to influence transmembrane transport and absorption, thus leading to the fact that blood concentration reaches peak time late, the bioavailability is low, and a large amount of drug prototypes are discharged out of the body through intestines, thus causing waste and environmental pollution. Along with the development of large-scale breeding industry, development of efficient tilmicosin preparation suitable for clinical first-line use is urgently needed.
Therefore, it is a technical problem to be solved by those skilled in the art to provide a tilmicosin preparation which is highly stable, efficient, free of bitter taste and capable of being easily mixed uniformly.
Disclosure of Invention
In view of the above, the invention provides an efficient double-layer coated pellet of tilmicosin and a preparation method thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
the tilmicosin high-efficiency double-layer coated micropill comprises a pill core, a quick-release medicine coating layer and a taste masking coating layer; wherein, the pill core comprises the following components in weight ratio: quick release drug coating: taste masking coating = 50-80:10-30:1-10;
wherein, the pill core comprises the following raw materials in parts by weight: 10-20 parts of tilmicosin, 25-50 parts of solid dispersing agent, 5-20 parts of inclusion agent and 1-10 parts of surfactant;
the quick-release medicine coating comprises the following raw materials in parts by weight: 1-10 parts of tilmicosin, 0-10 parts of solid dispersing agent, 10-20 parts of coating agent and 2-3 parts of coating material;
the taste masking coating layer comprises the following raw materials in parts by weight: 1-5 parts of coating material, 1-2 parts of sweetener and 1-3 parts of lubricant.
Preferably, the components are in weight proportion as a pill core: quick release drug coating: taste masking coating =(60-80)：(20-30)：(1-5)。
Further, the solid dispersing agent is a companion type composite auxiliary material solid dispersing agent.
Further, the solid dispersing agent of the mate composite auxiliary material is one or more of polyethylene glycol 8000, polyethylene glycol 6000, poloxamer 188, mono-diglycerol fatty acid ester, hydrogenated castor oil and copovidone.
The beneficial effects of adopting the further scheme are as follows: the adopted companion type composite auxiliary material solid dispersing agent is a medicine or food grade material, is safe and reliable, and has no side effect.
Further, the inclusion agent is one or more of beta cyclodextrin, hydroxypropyl beta cyclodextrin, polyethylene glycol, carbomer and hypromellose.
The beneficial effects of adopting the further scheme are as follows: the inclusion agent is cyclodextrin, and the inclusion technology is to use the barrel-shaped cavity space in the molecular structure and to use the novel solid dispersion technology to directionally disperse and include the medicine molecules in the barrel-shaped cavity space in the molecular structure to form stable solid dispersion microcapsules or pellets, which are also called as molecular capsules. The cyclodextrin has good non-toxic safety, more than 6 glucose are connected through alpha-1, 4 glycosidic bonds to form a barrel-shaped cavity space structure, and the cyclodextrin has the specificity of 'outer hydrophilcity and inner hydrophilcity', and according to the principle of compatibility of similar people, the outer hydrophilcity enables the cyclodextrin to be easily dissolved in water, and the inner hydrophilcity enables the cyclodextrin to attract and contain indissolvable drug molecules to enter the barrel-shaped cavity space structure to form a stable solid dispersion. The solid dispersion improves the solubility, stability and in vivo bioavailability of the medicine in water, and particularly can quickly release the medicine in animals to generate high blood concentration and bombardment sterilization effect on pathogenic bacteria. The technology has been applied in human pharmaceutical preparations for many years, and is mainly used for covering up the peculiar smell of the medicine, increasing the solubility and stability of insoluble medicine, improving the bioavailability of the medicine and the like.
Further, the surfactant is polyoxyethylene hydrogenated castor oil, and one or more of tween, sodium dodecyl sulfate and propylene glycol are mixed.
The beneficial effects of adopting the further scheme are as follows: the surfactant adopted by the invention can accelerate the release and dissolution of the medicine, and realize the function and curative effect of the medicine as soon as possible.
Further, the coating material is one or more of hypromellose, copovidone, polyacrylic resin latex and acrylic resin No. 2;
the sweetener is steviosin and the lubricant is talcum powder.
The beneficial effects of adopting the further scheme are as follows: the coating material adopted by the invention can effectively mask the peculiar smell of the medicine and increase the stability of the medicine.
The invention also provides a preparation method of the efficient tilmicosin double-layer coated pellet, which comprises the following steps:
(1) Weighing the raw materials according to the parts by weight;
(2) Heating and melting a solid dispersing agent and an inclusion agent in the pellet core material to obtain a melt 1;
(3) Adding tilmicosin into the melt 1, stirring and dissolving until the tilmicosin is clear, and then adding a surfactant, stirring, dissolving and clarifying to obtain a solution 2;
(4) Stirring the solution 2 at 70-80 ℃ until all components are uniformly dispersed, filtering the solution 2, setting the air inlet temperature to be 0-10 ℃, and preparing the tilmicosin pill core by a high-speed centrifugal atomizer and a cold spraying mode;
(5) Sieving tilmicosin pill core, taking 24-65 mesh, dissolving quick-release medicine coating material in ethanol solution, setting air inlet temperature at 45-55deg.C, and spray coating quick-release medicine coating on pill core by fluidized bed bottom;
(6) Dissolving the taste masking coating material in water to form latex with mass fraction of 30%, setting air inlet temperature at 45-55deg.C, and spray coating the latex to the surface of quick-release drug coating layer by fluidized bed to obtain tilmicosin high-efficiency double-layer coated pellet.
The method has the beneficial effects that: experiments show that the tilmicosin high-efficiency pellets prepared by the method have the advantages of no bitter taste, no peculiar smell, remarkably improved solubility and dissolution speed, uniform particle size, good flowability, no dust in the process of mixing materials, and easy uniform mixing with feed.
Further, the heating temperature in the step (2) is 60-90 ℃;
step (2) further comprises adding an inclusion agent in the pellet core material to melt 1.
Further, in the step (4), the stirring speed is 100-200r/min, and the stirring time is 20-180min.
Further, the volume fraction of the ethanol solution in the step (5) is 20%.
Compared with the prior art, the invention has the beneficial effects that:
(1) The tilmicosin high-efficiency double-layer coated pellet is prepared by combining a solid dispersion technology and an inclusion technology and adopting a melt atomization method, has no liquid solvent, short heat preservation time, does not need heat energy during spraying, is prepared only by a cold spraying mode, is simple and convenient to operate and low in cost compared with similar preparations, and is suitable for large-scale industrial production.
(2) The invention relates to an efficient double-layer coated pellet of tilmicosin, which consists of a pellet core, a quick-release medicine coating layer and a taste masking coating layer. The pill core is prepared by adopting a solid dispersion melting method, and tilmicosin is uniformly dispersed in the partner-type composite auxiliary materials at a molecular level, so that the bioavailability is higher; the quick-release medicine coating makes the release speed faster, and realizes the high-efficiency functional pill.
(3) The tilmicosin high-efficiency double-layer coated pellet changes insoluble medicines into soluble preparations, the inclusion process covers the peculiar smell of the medicines, the solid dispersion and the inclusion process are combined, the dissolution rate and the bioavailability of the medicines are greatly improved, various requirements of clinical mixing, drinking and concentrated preparation application can be met, and the tilmicosin high-efficiency double-layer coated pellet is convenient for clinical application and popularization.
(4) The tilmicosin high-efficiency double-layer coated pellet disclosed by the invention is green and safe in all of solid dispersing agents, inclusion agents, surfactants and the like, does not contain hormone, antibiotics and the like to influence food safety components, and is suitable for popularization and application in large-scale pig farms and industrialization.
(5) The invention discloses a tilmicosin high-efficiency double-layer coated pellet, which is found by comparing pharmacokinetics tests, and has the advantages of high absorption speed, quick response, high blood concentration and good curative effect in oral administration. The graph shows that the impact effect of the anti-biological drug blood drug peak sterilization can be achieved, and a plurality of parameter indexes all achieve the ideal effect of oral anti-biological drug treatment, so that the clinical drug application can be satisfied.
(6) The invention combines the solid dispersion technology and the cyclodextrin inclusion technology, the inclusion technology covers peculiar smell, the solid dispersion technology increases solubility and dissolution, the pollution-free and liquid solvent-free technology is adopted in the preparation process, the convenient cold spraying technology is used for preparing the efficient tilmicosin pellets for animals, and the pellets are subjected to secondary coating, so that the pellets have no peculiar smell completely. The preparation process has the advantages of low energy consumption, low cost, large production batch, green and pollution-free properties and the like. The prepared inclusion microcapsule has no bitter taste, improves the palatability of tilmicosin, reduces the irritation of tilmicosin to animal gastric mucosa, improves the compliance of animals to tilmicosin, has high dissolution rate, quick effect, high blood concentration, good curative effect and good stability, can completely meet the detection requirements of national standards, and practically solves the problems of inconvenient medicine use and the like in the large-scale cultivation process from the clinical point of view, and humanized meets the medicine use habit of a cultivator. The invention also provides a preparation method of the tilmicosin high-efficiency pellets for animals.
Drawings
FIG. 1 is a high-efficiency pellet of tilmicosin prepared by the invention;
FIG. 2 is a high-efficiency pellet of tilmicosin from company A;
FIG. 3 is a tilmicosin high-efficiency pellet from company B;
FIG. 4 is a graph showing the dissolution profile of tilmicosin pellets prepared according to the present invention in water;
FIG. 5 is a graph (0-72 hours) comparing the average drug time of tilmicosin and tilmicosin enteric coated particles of example 2 of the present invention;
FIG. 6 is a graph (0-36 hours) comparing the average drug time of tilmicosin and tilmicosin enteric coated particles of example 2 of the present invention;
FIG. 7 is a graph (0-24 hours) comparing the average drug time of tilmicosin and tilmicosin enteric coated particles of example 2 of the present invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The product prepared in example 1 was used in the test examples of the present invention.
Example 1
Efficient double-layer coated tilmicosin pellets
(1) Weighing the core material: 150kg of tilmicosin, 6000250kg of polyethylene glycol, 188180kg of poloxamer, 100kg of betacyclodextrin and 20kg of sodium dodecyl sulfate;
quick release drug coating material: 50kg of tilmicosin, 50kg of beta-cyclodextrin, 6000100kg of polyethylene glycol, 60kg of hypromellose and 20kg of copovidone;
taste masking coating material: 10kg of hydroxypropyl methylcellulose; 7kg of polyacrylic resin; 2kg of talcum powder; steviosin 1kg;
(2) Heating and melting a solid dispersing agent in the pill core material, and then adding a coating agent in the pill core material to obtain a melt 1;
(3) Adding tilmicosin into the melt 1, stirring and dissolving until the tilmicosin is clear, and then adding a surfactant, stirring, dissolving and clarifying to obtain a solution 2;
(4) Stirring solution 2 at 75deg.C for 30min under stirring at 100r/min, filtering solution 2, setting air inlet temperature at 5deg.C, and preparing tilmicosin pill core by high-speed centrifugal atomizer and cold spraying;
(5) Sieving tilmicosin pill core to obtain 30-65 mesh pill core, dissolving quick-release medicine coating material in ethanol solution, setting air inlet temperature at 50deg.C, and spray coating quick-release medicine coating on pill core by fluidized bed bottom;
(6) Dissolving the taste masking coating material in water to form latex with the mass fraction of 30%, setting the air inlet temperature to be 50 ℃, and coating the latex on the surface of the quick-release drug coating layer through the bottom spray of a fluidized bed to obtain the tilmicosin high-efficiency double-layer coated micropill.
Example 2
Efficient double-layer coated tilmicosin pellets
(1) Weighing the core material: 150kg of tilmicosin; 100kg of mono-diglyceride fatty acid ester; 250kg of hydrogenated castor oil; 188130kg of poloxamer; 100kg of hydroxypropyl betacyclodextrin; tween 80 20kg.
Quick release drug coating material: 50kg of tilmicosin; 70kg of beta-cyclodextrin; 100kg of hydroxypropyl methylcellulose; 20kg of copovidone;
taste masking coating material: 5kg of hydroxypropyl methylcellulose; 3kg of polyacrylic resin; talcum powder 1kg; steviosin 1kg;
(2) Heating and melting a solid dispersing agent in the pill core material, and then adding a coating agent in the pill core material to obtain a melt 1;
(3) Adding tilmicosin into the melt 1, stirring and dissolving until the tilmicosin is clear, and then adding a surfactant, stirring, dissolving and clarifying to obtain a solution 2;
(4) Stirring solution 2 at 70deg.C for 30min under 200r/min, dispersing uniformly, filtering solution 2, setting air inlet temperature at 3deg.C, and preparing tilmicosin pill core by high-speed centrifugal atomizer and cold spraying;
(5) Sieving tilmicosin pill core to obtain 65 mesh pill core, dissolving quick-release medicine coating material in ethanol solution, setting air inlet temperature at 55deg.C, and spray coating quick-release medicine coating on pill core by fluidized bed bottom;
(6) Dissolving the taste masking coating material in water to form latex with the mass fraction of 30%, setting the air inlet temperature to 55 ℃, and coating the latex on the surface of the quick-release drug coating layer through the bottom spray of a fluidized bed to obtain the tilmicosin high-efficiency double-layer coated pellet.
Example 3
Efficient double-layer coated tilmicosin pellets
(1) Weighing the core material: 120kg of tilmicosin; 140kg of copovidone; 8000150kg of polyethylene glycol; 188200kg of poloxamer; 40kg of polyoxyethylene hydrogenated castor oil;
quick release drug coating material: 80kg of tilmicosin; polyethylene glycol 600080kg; 80kg of hydroxypropyl methylcellulose; 30kg of hydroxypropyl betacyclodextrin; 30kg of copovidone;
taste masking coating material: 25kg of hydroxypropyl methylcellulose; 12kg of polyacrylic resin; 6kg of steviosin; 7kg of talcum powder;
(2) Heating and melting a solid dispersing agent in a pill core material to obtain a melt 1;
(3) Adding tilmicosin into the melt 1, stirring and dissolving until the tilmicosin is clear, and then adding a surfactant, stirring, dissolving and clarifying to obtain a solution 2;
(4) Stirring solution 2 at 80deg.C for 30min under 140r/min, dispersing uniformly, filtering solution 2, setting air inlet temperature at 2deg.C, and preparing into tilmicosin pill core by high-speed centrifugal atomizer and cold spraying;
(5) Sieving tilmicosin pill core to obtain 24 mesh pill core, dissolving quick-release medicine coating material in ethanol solution, setting air inlet temperature at 45deg.C, and spray coating quick-release medicine coating on pill core by fluidized bed bottom;
(6) Dissolving the taste masking coating material in water to form latex with the mass fraction of 30%, setting the air inlet temperature to 45 ℃, and coating the latex on the surface of the quick-release drug coating layer through the bottom spray of a fluidized bed to obtain the tilmicosin high-efficiency double-layer coated pellet.
Test example 1 drug particle size test:
the test method comprises the following steps: referring to a particle size determination method of tilmicosin premix of 2015 edition of Chinese animal pharmacopoeia, combining with internal control of products, selecting 24-mesh and 65-mesh sieves, weighing samples of different manufacturers, performing particle size screening on the medicines by the same method, evaluating the medicines with a qualification rate of 24-65 meshes, and optimizing the qualification rate of 24-65 meshes. The results of the particle size measurement are shown in Table 1 below.
TABLE 1 results of particle size determination of tilmicosin premix from different manufacturers
| Product name | The invention relates to a high-efficiency pellet of tilmicosin group | A enterprise product | B Enterprise product |
| Yield of percent of pass | 100％ | 64％ | 79％ |
Test results: by comparison, the tilmicosin-containing high-efficiency pellets have full and bright particles, uniform granularity and no fine powder, can provide a good mixing environment, and are easy to uniformly mix with granular medicines. Test example 2 drug bitter test:
the test method comprises the following steps: a small amount of tilmicosin premix drug was taken and placed at the tip of the tongue for taste, and evaluated within 5 seconds, with the results shown in table 2 below.
TABLE 2 bitter taste detection results of 20% tilmicosin premix from different manufacturers
| Product name | The invention relates to a high-efficiency pellet of tilmicosin group | A enterprise product | B Enterprise product |
| Taste and flavor of taste | No bitter and peculiar smell | The bitter taste is intense | Is especially sweet |
Test results: by comparison, the tilmicosin-containing high-efficiency pellets are not bitter within 5 seconds, so that the inclusion pellets are completely included, the taste masking effect is good, and the problem of drug irritation is solved.
Test example 3 alignment of pharmaceutical traits
(1) The test method comprises the following steps: the tilmicosin samples of 3 different manufacturers are respectively weighed, respectively placed under 100 times of electro-optical mirrors, observed and photographed, and the results are shown in figures 1, 2 and 3.
The tilmicosin high-efficiency pellets are round pellets, have smooth appearance, are uniform and compact in size and are not adhered to each other.
The product of enterprise A is irregular pill, which has unsmooth appearance, uneven and loose size and adhesion.
The product of enterprise B is irregular pill, its appearance is not smooth, its size is not symmetric and loose and is adhered mutually.
Test example 4 dissolution test
The test method comprises the following steps: according to the dissolution rate measurement method of China veterinary Pharmacopeia 2015, the high-efficiency tilmicosin pellets of examples 1, 2 and 3 are weighed, the samples of different factories are operated in the same method, the dissolution rate in water is measured, and the samples are sampled at 0, 5, 10, 15, 30, 45, 75 and 120 minutes, and the dissolution rate measurement results are shown in the following table 3 and fig. 4.
TABLE 3 comparative test results of dissolution in water of efficient tilmicosin pellets
Stability test
The high-efficiency tilmicosin pellets in example 2 are subjected to a normal temperature placement test and a 40 ℃ heat acceleration test according to the drug stability test guidelines under the 2015 item of Chinese animal pharmacopoeia, the normal temperature test is observed for 24 months, the 40 ℃ heat acceleration test is observed for 6 months, all quality indexes are in a qualified range, and the stability results are shown in the following table 4.
Table 4 florfenicol tilmicosin high-efficiency pellet microcapsule 40 ℃ stability test observation
In summary, the efficient tilmicosin pellets for animals are obviously superior to similar products in terms of bitterness, properties, granularity, dissolution rate, stability and the like, and the above description is further made in combination with specific preferred embodiments, and the specific implementation of the present invention is not to be considered as limited to these descriptions, and all similar processes and equivalent changes to the present invention should be considered as falling within the scope of protection of the present invention.
Test example 5
The invention discloses a high-efficiency pellet of tilmicosin, which is prepared from the following components in example 2 (Shennitimixin for short):
the tilmicosin high-efficiency pellets (abbreviated as Shenniu tilmicosin) prepared in the embodiment 2 of the invention and the domestic first-time tilmicosin enteric-coated particles are entrusted to the institute of animal husbandry and veterinary medicine in Lanzhou of China academy of agricultural sciences, and the absorption and metabolism characteristics of tilmicosin and enteric-coated particles are compared and evaluated in pig body in a pharmacokinetics comparison test, so that a basis is provided for preparing a reasonable clinical medication scheme.
5.1 Experimental protocol
Healthy three-way pigs, 16 pigs, are randomly divided into 2 groups (Shenniu tilmicin group; tilmicosin enteric granule control group), 8 of each group, and male and female are half. The administration dosage refers to the clinical recommended dosage and usage of tilmicosin pigs, and the feeding amount of the early-stage actual feed is combined to determine that each pig is 60mg/kgBW, and each group is subjected to one-time gastric lavage administration. Each pig blood sampling point is 20 time points of 0min, 15min, 30min, 45min, 1h, 1.25h, 1.5h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 36h, 48h, 72h and the like. The sample is anticoagulated by EDTA, plasma is separated, a Waters2695 high performance liquid chromatography system is adopted for detection, the experimental data are processed and counted by utilizing the full-automatic pharmacokinetic analysis software of Phoenix WinNonLin8.2, the AUC and Cmax are subjected to logarithmic transformation, and then the analysis of variance, double single-side t-test and calculation of relative bioavailability are carried out. Methodology studies showed that the regression equation was y= 26971x-196608, r 2 The linear range is 50-5000 ng/mL, the quantitative limit is 50ng/mL, the precision is less than 5%, the average recovery rate under the three concentrations of low, medium and high is 96.5+/-2.53%, 96.88 +/-1.25%, 105.3+/-1.85%, and the RSD% is less than 5%.
5.2 pharmacokinetic experiments
5.2.1 concentration at time of drug and Curve at time of drug
Determining and calculating the content of tilmicosin in pig plasma samples at different time points, and obtaining the results shown in Table 1; drawing a medicine time curve chart of tilmicosin by taking time as an x axis and tilmicosin concentration as a y axis, wherein the medicine time curve chart of tilmicosin in different time periods is shown in fig. 5 and 6.
TABLE 5 concentration of tilmicosin and tilmicosin enteric coated particles in pig plasma traditional Chinese medicine (. Mu.g/mL)
5.2.2 pharmacokinetic parameters
The experiment adopts a high performance liquid phase detection method to determine main parameters of pharmacokinetics of tilmicosin and tilmicosin enteric-coated particles in pigs, and a curve of the tilmicosin and tilmicosin enteric-coated particles accords with a non-atrioventricular model when the pigs are administrated in a single dose.
Tilmicosin and tilmicosin enteric granule reference drug main pharmacokinetic parameters, average maximum blood concentration C max 2.1+ -1.1 and 1.2+ -0.7 respectively; the delay time TLag is respectively 0.8+/-0.4 and 3.2+/-1.5; peak time T max 4.4+ -1.0 and 6.5+ -0.5 respectively; average drug elimination half-life T 1/2 8.4+ -6.3, 17.5+ -12.6, respectively; the average area under the curve AUC (0-24) is 14.77+ -4.48, 9.94+ -6.8, and the average area under the curve AUC (0-infinity) is 15.74+ -5.7, 12.1+ -9.5 respectively; the clearance CL/F is respectively as follows; 4.32+ -3.41, 3.01+ -2.81; the apparent distribution volumes V_F were 44.31.+ -. 34.26 and 66.41.+ -. 50.54, respectively, and the average residence times MRTlast were 8.5.+ -. 1.2 and 12.1.+ -. 3.1, respectively.
5.3 summary of experimental data
The above experimental parameters and data are summarized in Table 6, and the time-of-drug curve (0-24 hours) is shown in FIG. 7.
TABLE 6 results of comparative study of pharmacokinetics of tilmicosin and tilmicosin enteric coated particles
5.4 comprehensive analysis of Experimental data
5.4.1 absorption, distribution, metabolism
The peak time of the blood concentration of the Shennitimixing and tilmicosin enteric-coated particles is respectively 4.4 hours and 6.5 hours; half-lives were 8.4 hours, 17.5 hours, respectively; the clearance rate is respectively 4 hours and 3 hours; the average residence time was 8.5 hours and 12 hours, respectively. The data show that tilmicosin has quick response compared with tilmicosin enteric granule, wherein the peak time of the tilmicosin is 2 hours earlier; the oral clearance rate reaches 4 hours, the half-life reaches 8 hours, and the method accords with the drug release rule of oral antibiotics.
5.4.2 time and blood concentration
The highest blood concentration Cmax of the tilmicosin enteric-coated particles is 2.1 and 1.2 mug/ml respectively, and the data show that the blood concentration of the tilmicosin enteric-coated particles is up to 175%; the area under the curve when the oral administration was counted according to different time periods is shown in table 7.
TABLE 7 Curve area of tilmicosin and tilmicosin enteric coated granule
Description of data: tilmicosin is an enteric-coated particle of tilmicosin with a treatment effect of more than 2 times within 0-12 hours of oral administration; 1.5 times in the interval of 0-24 hours; the time period between 0 and 48 hours is 1.3 times.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (3)
1. The preparation method of the tilmicosin double-layer coated pellet is characterized by comprising the following steps of:
(1) Weighing the core material: 150kg of tilmicosin, 6000 kg of polyethylene glycol 250kg, 188 kg of poloxamer 188 kg, 100kg of betacyclodextrin and 20kg of sodium dodecyl sulfate;
quick release drug coating material: 50kg of tilmicosin, 50kg of betacyclodextrin, 6000 kg of polyethylene glycol, 60kg of hypromellose and 20kg of copovidone;
taste masking coating material: 10kg of hydroxypropyl methylcellulose; 7kg of polyacrylic resin; 2kg of talcum powder; steviosin 1kg;
(2) Heating and melting solid dispersing agent polyethylene glycol 6000 and poloxamer 188 in the pill core material, and then adding inclusion agent beta-cyclodextrin in the pill core material to obtain melt 1;
(3) Adding tilmicosin into the melt 1, stirring and dissolving until the tilmicosin is clear, and then adding surfactant sodium dodecyl sulfate, stirring, dissolving and clarifying to obtain a solution 2;
(4) Stirring solution 2 at 75deg.C for 30min under stirring at 100r/min, filtering solution 2, setting air inlet temperature at 5deg.C, and preparing tilmicosin pill core by high-speed centrifugal atomizer and cold spraying;
(5) Sieving tilmicosin pill core to obtain 30-65 mesh pill core, dissolving quick-release medicine coating material in ethanol solution, setting air inlet temperature at 50deg.C, and spray coating quick-release medicine coating on pill core by fluidized bed bottom;
(6) Dissolving the taste masking coating material in water to form latex with the mass fraction of 30%, setting the air inlet temperature to be 50 ℃, and coating the latex on the surface of the quick-release drug coating layer through the bottom spray of a fluidized bed to obtain the tilmicosin double-layer coated pellet.
2. The preparation method of the tilmicosin double-layer coated pellet is characterized by comprising the following steps of:
(1) Weighing the core material: 150kg of tilmicosin; 100kg of mono-diglyceride fatty acid ester; 250kg of hydrogenated castor oil; poloxamer 188 kg 130; 100kg of hydroxypropyl betacyclodextrin; tween 80 20kg;
quick release drug coating material: 50kg of tilmicosin; 70kg of beta-cyclodextrin; 100kg of hydroxypropyl methylcellulose; 20kg of copovidone;
taste masking coating material: 5kg of hydroxypropyl methylcellulose; 3kg of polyacrylic resin; talcum powder 1kg; steviosin 1kg;
(2) Heating and melting solid dispersing agent mono-diglycerol fatty acid ester, hydrogenated castor oil and poloxamer 188 in the pellet core material, and then adding inclusion agent hydroxypropyl betacyclodextrin in the pellet core material to obtain melt 1;
(3) Adding tilmicosin into the melt 1, stirring and dissolving until the tilmicosin is clear, and then adding a surfactant Tween 80, stirring, dissolving and clarifying to obtain a solution 2;
(4) Stirring solution 2 at 70deg.C for 30min under 200r/min, dispersing uniformly, filtering solution 2, setting air inlet temperature at 3deg.C, and preparing tilmicosin pill core by high-speed centrifugal atomizer and cold spraying;
(5) Sieving tilmicosin pill core to obtain 65 mesh pill core, dissolving quick-release medicine coating material in ethanol solution, setting air inlet temperature at 55deg.C, and spray coating quick-release medicine coating on pill core by fluidized bed bottom;
(6) Dissolving the taste masking coating material in water to form latex with the mass fraction of 30%, setting the air inlet temperature to 55 ℃, and coating the latex on the surface of the quick-release drug coating layer through the bottom spray of a fluidized bed to obtain the tilmicosin double-layer coated pellet.
3. The preparation method of the tilmicosin double-layer coated pellet is characterized by comprising the following steps of:
(1) Weighing the core material: 120kg of tilmicosin; 140kg of copovidone; polyethylene glycol 8000150kg; poloxamer 188200kg; 40kg of polyoxyethylene hydrogenated castor oil;
quick release drug coating material: 80kg of tilmicosin; polyethylene glycol 600080kg; 80kg of hydroxypropyl methylcellulose; 30kg of hydroxypropyl betacyclodextrin; 30kg of copovidone;
taste masking coating material: 25kg of hydroxypropyl methylcellulose; 12kg of polyacrylic resin; 6kg of steviosin; 7kg of talcum powder;
(2) Heating and melting solid dispersing agent copolyvidone, polyethylene glycol 8000 and poloxamer 188 in the pill core material to obtain melt 1;
(3) Adding tilmicosin into the melt 1, stirring and dissolving until the tilmicosin is clear, and then adding a surfactant polyoxyethylene hydrogenated castor oil, stirring, dissolving and clarifying to obtain a solution 2;
(4) Stirring solution 2 at 80deg.C for 30min under 140r/min, dispersing uniformly, filtering solution 2, setting air inlet temperature at 2deg.C, and preparing into tilmicosin pill core by high-speed centrifugal atomizer and cold spraying;
(5) Sieving tilmicosin pill core to obtain 24 mesh pill core, dissolving quick-release medicine coating material in ethanol solution, setting air inlet temperature at 45deg.C, and spray coating quick-release medicine coating on pill core by fluidized bed bottom;
(6) Dissolving the taste masking coating material in water to form latex with the mass fraction of 30%, setting the air inlet temperature to 45 ℃, and coating the latex on the surface of the quick-release drug coating layer through the bottom spray of a fluidized bed to obtain the tilmicosin double-layer coated pellet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211320346.0A CN115645376B (en) | 2022-10-26 | 2022-10-26 | Efficient double-layer coated tilmicosin pellets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211320346.0A CN115645376B (en) | 2022-10-26 | 2022-10-26 | Efficient double-layer coated tilmicosin pellets and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115645376A CN115645376A (en) | 2023-01-31 |
| CN115645376B true CN115645376B (en) | 2023-10-31 |
Family
ID=84990858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211320346.0A Active CN115645376B (en) | 2022-10-26 | 2022-10-26 | Efficient double-layer coated tilmicosin pellets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115645376B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116747206B (en) * | 2023-07-06 | 2024-02-20 | 广东彼迪药业有限公司 | Flunarizine hydrochloride capsule and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102160854A (en) * | 2011-04-15 | 2011-08-24 | 广东养宝生物制药有限公司 | Cyclodextrin-included florfenicol quick-release water-soluble powder preparation and preparation method thereof |
| CN105125524A (en) * | 2015-10-20 | 2015-12-09 | 中牧南京动物药业有限公司 | Tilmicosin enteric-coated pellets and preparation method thereof |
| WO2016044976A1 (en) * | 2014-09-22 | 2016-03-31 | 江苏大学 | Double-coating cyclosporine a sustained-release pellet preparation and preparation method therefor |
| CN108853025A (en) * | 2018-07-30 | 2018-11-23 | 佛山科学技术学院 | A kind of Tilmicosin solid dispersions and preparation method thereof |
| WO2019032057A1 (en) * | 2017-08-11 | 2019-02-14 | Vet Products Research And Innovation Center Company Limited | Method for preparing nano-particle of tilmicosin and product thereof |
| CN109953997A (en) * | 2019-04-22 | 2019-07-02 | 佛山科学技术学院 | A kind of preparation method of tilmicosin micro-capsule preparation |
| CN112656775A (en) * | 2021-02-02 | 2021-04-16 | 山东鲁抗舍里乐药业有限公司高新区分公司 | Preparation method of taste-masking coated tilmicosin premix |
-
2022
- 2022-10-26 CN CN202211320346.0A patent/CN115645376B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102160854A (en) * | 2011-04-15 | 2011-08-24 | 广东养宝生物制药有限公司 | Cyclodextrin-included florfenicol quick-release water-soluble powder preparation and preparation method thereof |
| WO2016044976A1 (en) * | 2014-09-22 | 2016-03-31 | 江苏大学 | Double-coating cyclosporine a sustained-release pellet preparation and preparation method therefor |
| CN105125524A (en) * | 2015-10-20 | 2015-12-09 | 中牧南京动物药业有限公司 | Tilmicosin enteric-coated pellets and preparation method thereof |
| WO2019032057A1 (en) * | 2017-08-11 | 2019-02-14 | Vet Products Research And Innovation Center Company Limited | Method for preparing nano-particle of tilmicosin and product thereof |
| CN108853025A (en) * | 2018-07-30 | 2018-11-23 | 佛山科学技术学院 | A kind of Tilmicosin solid dispersions and preparation method thereof |
| CN109953997A (en) * | 2019-04-22 | 2019-07-02 | 佛山科学技术学院 | A kind of preparation method of tilmicosin micro-capsule preparation |
| CN112656775A (en) * | 2021-02-02 | 2021-04-16 | 山东鲁抗舍里乐药业有限公司高新区分公司 | Preparation method of taste-masking coated tilmicosin premix |
Non-Patent Citations (1)
| Title |
|---|
| 替米考星固体分散体的制备与物相鉴定;巴娟 等;《中国兽药杂志》;第53卷(第1期);第44-49页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115645376A (en) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112716902B (en) | Florfenicol powder and preparation method thereof | |
| CN115645376B (en) | Efficient double-layer coated tilmicosin pellets and preparation method thereof | |
| CN108815123A (en) | A kind of curcumin solid dispersion and its preparation method and application | |
| CN1744881A (en) | Pharmaceutical compositions having reduced bitter taste | |
| CN110075082B (en) | Enrofloxacin quick-release pellet and preparation method thereof | |
| CN105168148A (en) | Homogeneous florfenicol particles and preparation method thereof | |
| CN109953997B (en) | Preparation method of tilmicosin preparation | |
| CN111700874A (en) | Enteric fast-release taste-masking granules of enrofloxacin and preparation method thereof | |
| CN104814931A (en) | Olaquindox slow release particle and preparing method and application thereof | |
| CN108853025B (en) | Tilmicosin solid dispersion and preparation method thereof | |
| CN107375247B (en) | Tilmicosin film-controlled enteric sustained-release preparation and preparation method thereof | |
| CN102526007B (en) | Florfenicol taste masking preparation and preparation method for same | |
| CN112220755A (en) | Doxycycline hydrochloride soluble powder and preparation method thereof | |
| CN111135153A (en) | Ursodeoxycholic acid capsule and preparation method thereof | |
| CN103877027A (en) | Cefuroxime axetil hot-melt coating composition and preparation method of composition | |
| CN105663131B (en) | A kind of Repaglinide metformin tablet medicament composition and preparation method thereof | |
| CN113041231B (en) | Tibipenem pivoxil fine granule composition and preparation method thereof | |
| CN112494460B (en) | Tilmicosin powder and preparation method thereof | |
| CN106109443B (en) | A kind of animal Ciprofloxacin Hydrochloride slow-releasing microcapsule and preparation method thereof | |
| CN105919960A (en) | Roxithromycin dispersible tablets and preparation method thereof | |
| CN105232485A (en) | Florfenicol enteric orally-disintegrating preparation and preparing method thereof | |
| CN103816123B (en) | A kind of CEFUROXIME AXETIL composition and method of making the same | |
| CN108478588B (en) | Tilmicosin slow-release enteric solvent and preparation method thereof | |
| CN105997894B (en) | Veterinary chlortetracycline premix and preparation method thereof | |
| CN105663054B (en) | A kind of Sitafloxacin hydrate granules agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |